SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical
company focused on developing best-in-class, oral therapies for the
treatment of chronic inflammatory and autoimmune diseases, today
announced the appointment of Tamar
Howson, a highly seasoned life sciences executive, to its
Board of Directors, effective October 11,
2019. With this addition, Immunic's Board now totals six
members.
"Tamar brings to Immunic more than thirty years of relevant
experience in corporate and business development, having worked
in-house, and as a consultant and Board member for a wide range of
companies in the biotechnology and pharmaceutical industries,"
stated Duane Nash, M.D., J.D.,
M.B.A., Chairman of the Board of Directors of Immunic. "Her vast
industry expertise and proven leadership capabilities make her a
valuable asset, and we look forward to leveraging her knowledge and
insights as we progress our clinical and preclinical pipeline
activities."
Ms. Howson is currently an Independent Director at MEI Pharma,
Inc. and Scientus Pharma Inc., and, until recently, was an
Independent Director at Organovo Holdings, Inc. Earlier, she was a
Senior Advisor on the transaction team at JSB-Partners, providing
business development support to life sciences companies. Before
that, she served as Executive Vice President, Corporate Business
Development at Lexicon Pharmaceuticals, Inc. Prior, Ms. Howson was
Senior Vice President, Corporate and Business Development at
Bristol-Myers Squibb Company, responsible for worldwide oversight
and management of the identification, evaluation and negotiation of
mergers and acquisitions, licensing and other external alliance
activities. Additionally, Ms. Howson spent nearly a decade at
SmithKline Beecham, where she served as Senior Vice President and
Director, Business Development and managed the company's
USD 100 million venture capital fund,
SR One.
During her career, Ms. Howson has also served on the boards of
companies including Actavis Pharma, Inc., ContraVir
Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., Enzymotec Ltd.,
Idenix Pharmaceuticals, Inc., IPM-International Partnership for
Microbicides and OXiGENE, Inc.
Ms. Howson earned a Bachelor of Science in chemical engineering
from the Technion - Israeli Institute of Technology, a Master of
Science in chemical engineering from the City
College of New York and a Master of Business Administration
from Columbia University.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a
clinical-stage biopharmaceutical company developing a pipeline of
selective oral immunology therapies aimed at treating chronic
inflammatory and autoimmune diseases, including relapsing-remitting
multiple sclerosis, ulcerative colitis, Crohn's disease, and
psoriasis. The company is developing three small molecule products:
IMU-838 is a selective immune modulator that inhibits the
intracellular metabolism of activated immune cells by blocking the
enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856
targets the restoration of the intestinal barrier function.
Immunic's lead development program, IMU-838, is in phase 2 clinical
development for relapsing-remitting multiple sclerosis and
ulcerative colitis, with an additional phase 2 trial planned in
Crohn's disease. An investigator-sponsored proof-of-concept
clinical trial for IMU-838 in primary sclerosing cholangitis is
ongoing at the Mayo Clinic. For further information, please visit:
www.immunic-therapeutics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
Immunic's clinical and preclinical pipeline activities and the
structure and composition of its board. Immunic may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, risks
and uncertainties associated with the ability to project future
cash utilization and reserves needed for contingent future
liabilities and business operations, the availability of sufficient
resources to meet business objectives and operational requirements,
the fact that the results of earlier studies and trials may not be
predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual property,
risks related to the drug development and the regulatory approval
process and the impact of competitive products and technological
changes. A further list and descriptions of these risks,
uncertainties and other factors can be found in the section
captioned "Item 1A. Risk Factors," in the company's Current Report
on Form 8-K filed on July 17, 2019,
and in the company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov or ir.immunic-therapeutics.com/sec-filings. Any
forward-looking statement made in this release speaks only as of
the date of this release. Immunic disclaims any intent or
obligation to update these forward-looking statements to reflect
events or circumstances that exist after the date on which they
were made. Immunic expressly disclaims all liability in respect to
actions taken or not taken based on any or all the contents of this
press release.
Contact Information
Immunic, Inc.
Jessica Breu
Manager IR and Communications
+49 89 250 0794 69
jessica.breu@immunic.de
Or
Rx Communications Group
Melody
Carey
+1-917-322-2571
immunic@rxir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunic-inc-expands-board-of-directors-with-appointment-of-industry-veteran-tamar-howson-300938251.html
SOURCE Immunic, Inc.